Telix Pharmaceuticals (ASX: TLX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Telix Pharmaceuticals Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Telix Pharmaceuticals (ASX: TLX)
Latest News
Healthcare Shares
Telix share price hits record high on strong quarter and guidance upgrade
Healthcare Shares
Up 66% in FY24, will Telix Pharmaceuticals shares continue?
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
3 ASX All Ords shares rocketing over 10% today
Share Gainers
Why Ora Banda, Paladin Energy, Seven Group, and Telix shares are charging higher
Record Highs
CBA and 7 other ASX 200 shares smashing new highs on Thursday
Record Highs
Why is the Telix Pharmaceuticals share price rocketing 15% to a record high?
Share Gainers
Best 3 ASX 200 healthcare shares for price growth in FY24
Share Gainers
Here are the top 10 ASX 200 shares today
Broker Notes
9 ASX All Ords shares lifted to 'strong buy' consensus ratings in June
Healthcare Shares
Bell Potter names the best ASX healthcare stocks to buy in FY25
Share Market News
Here are the top 10 ASX 200 shares today
Frequently Asked Questions
-
No, Telix does not pay dividends at this time.
-
Telix Pharmaceuticals Ltd listed on the ASX on 15 November 2017.
TLX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Telix Pharmaceuticals
Telix Pharmaceuticals Ltd (ASX: TLX) is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic ('theranostic') products using targeted radiation. This process treats cancerous or diseased cells, an alternative approach to many cancer therapies which also attack healthy tissue at the same time.
Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent Illuccix. It is working to get Illuccix approved for sale in the UK and Europe.
The company also has more than 20 clinical trials underway worldwide. Telix's research and development is focused on prostate, renal (kidney), glioblastoma (brain), and hematologic (bone marrow conditioning) cancers, as well as rare diseases. The company is headquartered in Australia with offices in Belgium, Japan, Switzerland, and the United States.
